Organogenesis Holdings Inc
ORGO
View Detailed Chart
2.290USD
0.0000.00%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
85.88MMarket Cap
14.50P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
-7.29%
1 Month
-23.67%
6 Months
-45.73%
Year to Date
-55.79%
1 Year
-49.11%
View Detailed Chart
TradingKey Stock Score of Organogenesis Holdings Inc
Currency: USD Updated: 2026-03-27Key Insights
Organogenesis Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organogenesis Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Organogenesis Holdings Inc Highlights
StrengthsRisks
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.25% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 564.17M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 14.50, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 69.93M shares, decreasing 12.15% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 6.69K shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
8.000
Target Price
+230.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Organogenesis Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Organogenesis Holdings Inc Info
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Ticker SymbolORGO
CompanyOrganogenesis Holdings Inc
CEOGillheeney (Gary S)
Websitehttps://investors.organogenesis.com
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67902.800
+1281.400 (+1.92%)
251.670
-23.670 (-8.60%)
2070.910
+50.210 (+2.48%)
355.280
-6.550 (-1.81%)
4582.850
+72.070 (+1.60%)
101.141
-3.121 (-2.99%)
1.147
+0.001 (+0.08%)
159.661
+0.002 (+0.00%)
